help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenman, Y.
Right arrow Articles by Melmed, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenman, Y.
Right arrow Articles by Melmed, S.

Journal of Clinical Endocrinology & Metabolism, Vol 79, 724-729, Copyright © 1994 by Endocrine Society

ARTICLES

Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage

Y Greenman and S Melmed
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048-1865.

The expression of three somatostatin receptor subtypes, SSTR3, SSTR4, and SSTR5, was evaluated in 33 pituitary tumor specimens. SSTR3 expression was studied by reverse transcription coupled to polymerase chain reaction, whereas SSTR4 and SSTR5 expression was determined by ribonuclease protection assay. SSTR3 was expressed in 6 of 7 GH- secreting tumors, all 8 clinically nonfunctioning tumors, all 3 prolactinomas, and 1 of 2 ACTH-secreting tumors tested. Eight nonfunctioning adenomas had undetectable messenger ribonucleic acid levels of SSTR4, and only 1 of them expressed SSTR5. SSTR4 expression was also undetectable in 11 GH-secreting tumors, 3 prolactinomas, and 1 ACTH-secreting tumor tested. In contrast, SSTR5 was highly expressed in 10 of 11 GH-secreting adenomas and 1 prolactinoma. Two prolactinomas and 1 ACTH-secreting tumor had low levels of expression of SSTR5. The widespread pituitary adenoma expression of SSTR3, regardless of hormonal secretory type, suggests that SSTR3 might be involved in a somatostatin action(s) other than GH or TSH regulation. SSTR5 is expressed predominantly in mammosomatotroph-derived tumors, suggesting that this receptor subtype may be an important determinant of GH secretion in acromegaly.


This article has been cited by other articles:


Home page
 Eur J EndocrinolHome page
A. Pokrajac, J. Frystyk, A. Flyvbjerg, and P. J Trainer
Pituitary-independent effect of octreotide on IGF1 generation
Eur. J. Endocrinol., April 1, 2009; 160(4): 543 - 548.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, and S. Savastano
Medical therapy for clinically non-functioning pituitary adenomas
Endocr. Relat. Cancer, December 1, 2008; 15(4): 905 - 915.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. D. Murray and S. Melmed
A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2957 - 2968.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T. Florio, F. Barbieri, R. Spaziante, G. Zona, L. J Hofland, P. M van Koetsveld, R. A Feelders, G. K Stalla, M. Theodoropoulou, M. D Culler, et al.
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
Endocr. Relat. Cancer, June 1, 2008; 15(2): 583 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Fusco, G. Gunz, P. Jaquet, H. Dufour, A. L. Germanetti, M. D Culler, A. Barlier, and A. Saveanu
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas
Eur. J. Endocrinol., May 1, 2008; 158(5): 595 - 603.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
U. Plockinger, S. Albrecht, C. Mawrin, W. Saeger, M. Buchfelder, S. Petersenn, and S. Schulz
Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1203 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Colao, M. Filippella, R. Pivonello, C. Di Somma, A. Faggiano, and G. Lombardi
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours
Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S57 - S63.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
G. F Taboada, R. M Luque, W. Bastos, R. F C Guimaraes, J. B Marcondes, L. M C Chimelli, R. Fontes, P. J P Mata, P. N. Filho, D. P Carvalho, et al.
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas
Eur. J. Endocrinol., January 1, 2007; 156(1): 65 - 74.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. L. Batista, X. Zhang, R. Gejman, P. J. Ansell, Y. Zhou, S. A. Johnson, B. Swearingen, E. T. Hedley-Whyte, C. A. Stratakis, and A. Klibanski
The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4482 - 4488.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao
Advances in the Treatment of Prolactinomas
Endocr. Rev., August 1, 2006; 27(5): 485 - 534.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
E Thodou, G Kontogeorgos, D Theodossiou, and M Pateraki
Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas.
J. Clin. Pathol., March 1, 2006; 59(3): 274 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
A. P. Heaney
Pituitary tumour pathogenesis.
Br. Med. Bull., January 1, 2006; 75-76: 81 - 97.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, et al.
Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6156 - 6161.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L. J Hofland, J. van der Hoek, R. Feelders, M. O van Aken, P. M van Koetsveld, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, W. W de Herder, et al.
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5
Eur. J. Endocrinol., April 1, 2005; 152(4): 645 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
M J Acosta-Gomez, M A Muros, J M Llamas-Elvira, A Ramirez, S Ortega, G Sabatel, C Ramos, and A de la Riva-Aguilar
The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours
Br. J. Radiol., February 1, 2005; 78(926): 110 - 115.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke
Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. D. Murray, K. Kim, S.-G. Ren, I. Lewis, G. Weckbecker, C. Bruns, and S. Melmed
The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion
J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3027 - 3032.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Hofland, J. van der Hoek, P. M. van Koetsveld, W. W. de Herder, M. Waaijers, D. Sprij-Mooij, C. Bruns, G. Weckbecker, R. Feelders, A.-J. van der Lely, et al.
The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas in Vitro
J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1577 - 1585.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Yan, M. E. E. Jones, M. Hernandez, D. Liu, E. R. Simpson, and C. Chen
Functional Modification of Pituitary Somatotropes in the Aromatase Knockout Mouse and the Effect of Estrogen Replacement
Endocrinology, February 1, 2004; 145(2): 604 - 612.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S.-G. Ren, J. Taylor, J. Dong, R. Yu, M. D. Culler, and S. Melmed
Functional Association of Somatostatin Receptor Subtypes 2 and 5 in Inhibiting Human Growth Hormone Secretion
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4239 - 4245.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. J. Hofland and S. W. J. Lamberts
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Endocr. Rev., February 1, 2003; 24(1): 28 - 47.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
A.-M. O'Carroll
Localization of Messenger Ribonucleic Acids for Somatostatin Receptor Subtypes (sstr1-5) in the Rat Adrenal Gland
J. Histochem. Cytochem., January 1, 2003; 51(1): 55 - 60.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. U. Freda
Somatostatin Analogs in Acromegaly
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. C. Danila, J. N. S. Haidar, X. Zhang, L. Katznelson, M. D. Culler, and A. Klibanski
Somatostatin Receptor-Specific Analogs: Effects on Cell Proliferation and Growth Hormone Secretion in Human Somatotroph Tumors
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2976 - 2981.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Saveanu, G. Gunz, H. Dufour, P. Caron, F. Fina, L. Ouafik, M. D. Culler, J. P. Moreau, A. Enjalbert, and P. Jaquet
BIM-23244, a Somatostatin Receptor Subtype 2- and 5-Selective Analog with Enhanced Efficacy in Suppressing Growth Hormone (GH) from Octreotide-Resistant Human GH-Secreting Adenomas
J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 140 - 145.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
S. Park, J. Kamegai, T. A. Johnson, L. A. Frohman, and R. D. Kineman
Modulation of Pituitary Somatostatin Receptor Subtype (sst1-5) Messenger Ribonucleic Acid Levels by Changes in the Growth Hormone Axis
Endocrinology, October 1, 2000; 141(10): 3556 - 3563.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy
Prolactin: Structure, Function, and Regulation of Secretion
Physiol Rev, October 1, 2000; 80(4): 1523 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Schulz, S. U. Pauli, S. Schulz, M. Handel, K. Dietzmann, R. Firsching, and V. Hollt
Immunohistochemical Determination of Five Somatostatin Receptors in Meningioma Reveals Frequent Overexpression of Somatostatin Receptor Subtype sst2A
Clin. Cancer Res., May 1, 2000; 6(5): 1865 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Jaquet, A. Saveanu, G. Gunz, F. Fina, A. J. Zamora, M. Grino, M. D. Culler, J. P. Moreau, A. Enjalbert, and L'H. Ouafik
Human Somatostatin Receptor Subtypes in Acromegaly: Distinct Patterns of Messenger Ribonucleic Acid Expression and Hormone Suppression Identify Different Tumoral Phenotypes
J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 781 - 792.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Brucker-Davis, E. H. Oldfield, M. C. Skarulis, J. L. Doppman, and B. D. Weintraub
Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 476 - 486.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Nielsen, S. Mellemkjær, L. M. Rasmussen, T. Ledet, J. Astrup, J. Weeke, and J. O. L. Jørgensen
Gene Transcription of Receptors for Growth Hormone-Releasing Peptide and Somatostatin in Human Pituitary Adenomas
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2997 - 3000.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
N. Kimura, S. Tomizawa, K. N. Arai, and N. Kimura
Chronic Treatment with Estrogen Up-Regulates Expression of sst2 Messenger Ribonucleic Acid (mRNA) but Down-Regulates Expression of sst5 mRNA in Rat Pituitaries
Endocrinology, April 1, 1998; 139(4): 1573 - 1580.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
E Kouroumalis, P Skordilis, K Thermos, A Vasilaki, J Moschandrea, and O N Manousos
Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study
Gut, March 1, 1998; 42(3): 442 - 447.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. J. Hofland, W. W. de Herder, H. A. Visser-Wisselaar, C. van Uffelen, M. Waaijers, J. Zuyderwijk, P. Uitterlinden, M. J. M. Kros, P. M. van Koetsveld, and S. W. J. Lamberts
Dissociation between the Effects of Somatostatin (SS) and Octapeptide SS-Analogs on Hormone Release in a Small Subgroup of Pituitary- and Islet Cell Tumors
J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3011 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Shimon and S. Melmed
Pituitary Tumor Pathogenesis
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. B. Ain, K. D. Taylor, S. Tofiq, and G. Venkataraman
Somatostatin Receptor Subtype Expression in Human Thyroid and Thyroid Carcinoma Cell Lines
J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1857 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. A. Visser-Wisselaar, C. J. C. van Uffelen, P. M. van Koetsveld, E. G. R. Lichtenauer-Kaligis, A. M. Waaijers, P. Uitterlinden, D. M. Mooy, S. W. J. Lamberts, and L. J. Hofland
17-{beta}-Estradiol-Dependent Regulation of Somatostatin Receptor Subtype Expression in the 7315b Prolactin Secreting Rat Pituitary Tumor in Vitro and in Vivo
Endocrinology, March 1, 1997; 138(3): 1180 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. W.J. Lamberts, A.-J. van der Lely, W. W. de Herder, and L. J. Hofland
Octreotide
N. Engl. J. Med., January 25, 1996; 334(4): 246 - 254.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1994 by The Endocrine Society